Goldman Sachs Group Analysts Give Novartis (NOVN) a CHF 98 Price Target

Goldman Sachs Group set a CHF 98 price target on Novartis (VTX:NOVN) in a report released on Friday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. Jefferies Financial Group set a CHF 105 price objective on Novartis and gave the company a buy rating in a report on Wednesday, March 27th. JPMorgan Chase & Co. set a CHF 85 price target on Novartis and gave the stock a sell rating in a research note on Wednesday, April 3rd. Kepler Capital Markets set a CHF 94 price target on Novartis and gave the stock a buy rating in a research note on Wednesday, January 30th. Barclays set a CHF 75 price target on Novartis and gave the stock a sell rating in a research note on Monday, April 8th. Finally, UBS Group set a CHF 85 price target on Novartis and gave the stock a neutral rating in a research note on Friday, January 18th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the stock. Novartis has a consensus rating of Hold and an average target price of CHF 90.33.

Novartis has a 1-year low of CHF 72.45 and a 1-year high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

See Also: Certificate of Deposit (CD) For Risk Adverse Investors?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.